Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
165.04
+8.39 (5.36%)
At close: Nov 13, 2026, 4:00 PM EST
165.91
+0.87 (0.53%)
After-hours: Nov 13, 2026, 7:59 PM EST
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 30 analysts polled by S&P Global, Alnylam Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $299.96. The average 1-year stock price forecast is 81.75% higher than the current stock price, while the lowest is $180 (+9.06%) and the highest is $455 (+175.69%).
Price Target: $299.96 (+81.75%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 16 | 16 | 15 | 14 |
| Buy | 7 | 8 | 7 | 6 | 7 | 7 |
| Hold | 8 | 6 | 6 | 7 | 8 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 28 | 29 | 29 | 30 | 30 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $455 | Buy | Reiterates | $455 | +175.69% | Nov 12, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $410 | Buy | Reiterates | $410 | +148.42% | Nov 10, 2026 |
| Citi | Citi | Buy Maintains $320 → $250 | Buy | Maintains | $320 → $250 | +51.48% | Nov 9, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $325 → $290 | Hold | Maintains | $325 → $290 | +75.71% | Nov 6, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Nov 5, 2026 |
Financial Forecast
Revenue This Year
5.44B
from 3.71B
Increased by 46.57%
Revenue Next Year
6.53B
from 5.44B
Increased by 19.91%
EPS This Year
22.68
from 5.08
Increased by 346.54%
EPS Next Year
10.83
from 22.68
Decreased by -52.25%
EPS and Forward PE are based on non-GAAP adjusted numbers.